Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Sell at BidaskClub

Share on StockTwits

Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday, BidAskClub reports.

VRCA has been the topic of several other research reports. Needham & Company LLC initiated coverage on shares of Verrica Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $20.00 price target on the stock. ValuEngine upgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 17th. Zacks Investment Research upgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Thursday, March 12th. Finally, HC Wainwright restated a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, March 17th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $18.33.

Verrica Pharmaceuticals stock opened at $11.66 on Friday. The firm has a market cap of $292.20 million, a price-to-earnings ratio of -10.32 and a beta of 3.72. Verrica Pharmaceuticals has a 1 year low of $6.79 and a 1 year high of $18.67. The firm’s 50 day moving average price is $12.16 and its two-hundred day moving average price is $14.01.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Friday, March 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.01). Analysts predict that Verrica Pharmaceuticals will post -2.3 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen Asset Management LLC grew its position in Verrica Pharmaceuticals by 5.7% during the 4th quarter. Nuveen Asset Management LLC now owns 46,265 shares of the company’s stock worth $735,000 after purchasing an additional 2,510 shares in the last quarter. Geode Capital Management LLC grew its position in Verrica Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 163,235 shares of the company’s stock worth $2,593,000 after purchasing an additional 19,510 shares in the last quarter. Alliancebernstein L.P. purchased a new position in Verrica Pharmaceuticals during the 4th quarter worth approximately $160,000. Goldman Sachs Group Inc. grew its position in Verrica Pharmaceuticals by 32.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 33,393 shares of the company’s stock worth $531,000 after purchasing an additional 8,139 shares in the last quarter. Finally, UBS Group AG grew its position in Verrica Pharmaceuticals by 34.1% during the 4th quarter. UBS Group AG now owns 18,714 shares of the company’s stock worth $298,000 after purchasing an additional 4,760 shares in the last quarter. Hedge funds and other institutional investors own 35.41% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Recommended Story: Strike Price

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BidaskClub Upgrades eBay  to “Hold”
BidaskClub Upgrades eBay to “Hold”
Madison Square Garden Co Forecasted to Earn Q2 2022 Earnings of $3.87 Per Share
Madison Square Garden Co Forecasted to Earn Q2 2022 Earnings of $3.87 Per Share
Brokers Issue Forecasts for Genesco Inc.’s Q4 2021 Earnings
Brokers Issue Forecasts for Genesco Inc.’s Q4 2021 Earnings
National Bank Financial Equities Analysts Reduce Earnings Estimates for Cae Inc
National Bank Financial Equities Analysts Reduce Earnings Estimates for Cae Inc
StoneCo  Rating Lowered to Strong Sell at BidaskClub
StoneCo Rating Lowered to Strong Sell at BidaskClub
FY2021 EPS Estimates for Rogers Communications Inc. Cut by Desjardins
FY2021 EPS Estimates for Rogers Communications Inc. Cut by Desjardins


© 2006-2020 Ticker Report